my country’s first completely self-developed aerospace “artificial heart” has been approved for listing, known as “the price is close to the people, reliable and easy to use”

IT House News on July 14th, according to news from Tianjin Economic and Technological Development Zone, on July 13th, key technology enterprises in Tianjin Economic and Technological Development ZoneAerospace Taixin Technology Co., Ltd.(hereinafter referred to as Aerospace Taixin) developed my country’s first artificial heart “Rocket Heart” with completely independent intellectual property rights –HeartCon Implantable Left Ventricular Assist System(hereinafter referred to as “Rocket Heart”) was successfully approved for listing and obtained the National Class III Medical Device Product Registration Certificate.

According to reports, the artificial heart has completely independent intellectual property rights.It is a left ventricular assist product that is completely independently developed and produced, and is independently controllable.. Up to now, HeartCon ranks first in the number of implants among similar products in China, and has completed 50 clinical trials of artificial hearts.

Heart failure is a rapidly growing heart disease, and is the end-stage manifestation of many types of cardiovascular diseases. Some data show that there are conservative estimates of 16 million heart failure patients in my country, of which end-stage heart failure patients account for 5-7% and are still increasing. Traditional treatment of end-stage heart failure has poor outcomes and high mortality. Although heart transplantation is a better treatment, it is far from meeting the needs of patients due to the severe shortage of heart donors.The number of heart transplants in my country is only about 500 every year, and a large number of patients die while waitingWith the emergence of durable and reliable mechanical assisted circulation devices, left ventricular assist device (LVAD) has become an effective new treatment method for patients with end-stage heart failure. It has been widely used abroad and has become a new choice for heart failure patients.

Aerospace Taixin Technology Co., Ltd. is committed to providing a full-cycle mechanical circulatory support treatment plan for patients with heart failure. Using 50 years of technical accumulation in aerospace rocket servo control, the HeartCon implantable left ventricular assist system hasSmall size, light weight, low temperature rise, good hemolysis and stable qualityFeatures, all technical indicators have reached the international first-class level. In 2013, the experimental sheep “Tianjiu” survived healthy for 120 days, setting five firsts, including the longest survival record in China. In 2018, the product passed the special approval for innovative medical devices.

IT House learned that China Aerospace Science and Technology Corporation called the artificial heart “Affordable, reliable and easy to use”, we can look forward to the evaluation of patients after the market.